Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Valine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.88 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 3/20 | 0.35 |
| ▸ | GABRD | O14764 | 3/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL18051144 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1FFAR3 | |
| Valine SCHEMBL11388654 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1FFAR3 | |
| Valine SCHEMBL7610657 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1FFAR3 | |
| Valine SCHEMBL18051145 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1FFAR3 | |
| Valine SCHEMBL7610659 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1FFAR3 | |
| Valine SCHEMBL4736126 | 0.97 | SLC7A5 (0.83) | SLC7A5SLC1A3SLC1A2SLC1A1FFAR3 | |
| Valine SCHEMBL9723033 | 0.94 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL8516 | 0.94 | — | — | |
| Valine SCHEMBL1813972 | 0.94 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL43678 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562974-B1 | PROCESSES FOR PREPARING C-7 SUBSTITUTED 5-ANDROSTENES | PHARMACIA & UPJOHN CO LLC (US) | 2007-02-21 | — | — | EP | disclosed |
| CN-1694896-A | Processes for preparing C-7 substituted 5-androstenes | UPJOHN CO (US) | 2005-11-09 | — | — | CN | disclosed |
| EP-1562974-A1 | PROCESSES FOR PREPARING C-7 SUBSTITUTED 5-ANDROSTENES | Pharmacia & Upjohn Company LLC (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004043986-A1 | PROCESSES FOR PREPARING C-7 SUBSTITUTED 5-ANDROSTENES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040097475-A1 | Reacting steroid intermediate with nucleophilic reagent in presence of Lewis acid catalyst to produce 7-substituted steroid compound | PHARMACIA & UPJOHN COMPANY | 2004-05-20 | — | — | US | disclosed |
| EP-0870082-A1 | ENZYMATIC METHOD FOR DYEING | NOVO NORDISK BIOCHEM NORTH AMERICA (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023684-A1 | ENZYMATIC METHOD FOR DYEING | NOVO NORDISK BIOCHEM NORTH AMERICA, INC. (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097475-A1 | Reacting steroid intermediate with nucleophilic reagent in presence of Lewis acid catalyst to produce 7-substituted steroid compound | CYP17A1, HSD17B7, NR5A1 | SLC7A5 1658/4885SLC1A3 4453/4885SLC1A2 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.